Form 4: Foghorn Therapeutics CPO Granted 230,000 Stock Options

Foghorn Therapeutics' Chief People Officer, Carlos Costa, was granted 230,000 stock options with an exercise price of $5.71, vesting over four years.

Summary

• Carlos Costa, Chief People Officer of Foghorn Therapeutics Inc. (FHTX), was granted 230,000 stock options.
• The options have an exercise price of $5.71 per share.
• The transaction date for the grant was January 30, 2026.
• The options will vest as to 25% of the underlying shares on January 30, 2027, and then at a rate of 6.25% of the underlying shares on the first day of each calendar quarter thereafter.
• The expiration date for these options is January 29, 2036.
• Following this transaction, Carlos Costa beneficially owns 230,000 derivative securities directly.
• A Limited Power of Attorney was granted by Carlos Costa on December 1, 2025, to Michael LaCascia, Adrian Gottschalk, and Samantha Macina to handle SEC filings on his behalf.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices aimed at retaining key talent and aligning management incentives with long-term shareholder value, without indicating any immediate operational changes.

Positives

• The grant of 230,000 stock options to the Chief People Officer aligns executive incentives with shareholder value.
• The vesting schedule over four years (initial 25% after one year, then quarterly) promotes long-term retention of a key executive.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, designed to attract, retain, and incentivize key talent by aligning their interests with the long-term performance of the company.

Stakeholder Impact

• Shareholders: Potential long-term benefit from incentivized executive performance.
• Employees: May signal stability in executive leadership and standard compensation practices.
• Management: Direct impact on Carlos Costa's compensation and long-term incentives.

Next Steps

• The stock options will begin vesting on January 30, 2027, with subsequent quarterly vesting periods.

Key Dates

Recommendation

This Form 4 filing reports a routine executive stock option grant, which is a standard compensation practice and does not provide new information significant enough to alter an investment thesis. It primarily serves to align executive incentives with long-term company performance, reinforcing a 'hold' stance for investors awaiting more substantive operational or financial updates.

Keywords

Foghorn Therapeutics, FHTX, Carlos Costa, Chief People Officer, Stock Options, Executive Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting Schedule